Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting Cancer-Specific Mutations with RNA-Triggered Chromatin Shredding.

Nature·2026
Same author

Deep learning models built from PSMA PET of the primary tumor can predict synchronous and metachronous prostate cancer metastases.

PloS one·2026
Same author

A quantitative framework to assess the potential of earlier cancer detection to improve cancer survival.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same author

Toward a Random Background for Ligand Optimization.

bioRxiv : the preprint server for biology·2026
Same author

Selective Elimination of TP53 Mutant Cells by Transcript-Activated Chromatin Shredding.

bioRxiv : the preprint server for biology·2026
Same author

Identifying therapeutic targets in low-grade serous ovarian carcinomas with no specific molecular profile.

The Journal of pathology·2026

Related Experiment Video

Updated: Dec 8, 2025

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

17.0K

Autoantibody Landscape in Patients with Advanced Prostate Cancer.

William S Chen1,2, Winston A Haynes3, Rebecca Waitz3

  • 1Department of Radiation Oncology, University of California San Francisco, San Francisco, California.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|September 24, 2020
PubMed
Summary

This study profiled autoantibodies in metastatic castration-resistant prostate cancer, identifying novel tumor-specific antigens and epitopes. These findings advance understanding of cancer immunity and potential immunotherapy targets.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.6K
Isolation, Culture, and Characterization of Prostate Cancer-Associated Fibroblasts
09:43

Isolation, Culture, and Characterization of Prostate Cancer-Associated Fibroblasts

Published on: August 1, 2025

582

Related Experiment Videos

Last Updated: Dec 8, 2025

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

17.0K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.6K
Isolation, Culture, and Characterization of Prostate Cancer-Associated Fibroblasts
09:43

Isolation, Culture, and Characterization of Prostate Cancer-Associated Fibroblasts

Published on: August 1, 2025

582

Area of Science:

  • Oncology
  • Immunology
  • Genomics

Background:

  • Autoantibodies in cancer correlate with T-cell responses and immunotherapy outcomes.
  • Characterizing the antibody landscape in metastatic castration-resistant prostate cancer (mCRPC) is crucial.

Purpose of the Study:

  • To comprehensively analyze the autoantibody repertoire in mCRPC.
  • To identify novel tumor-specific antigens and epitopes associated with prostate cancer.

Main Methods:

  • Serum antibody epitope repertoire analysis (SERA) on 72 mCRPC patients and 1,157 controls.
  • Whole-genome sequencing of tumor and germline DNA to identify somatic mutations.
  • Protein-based immunome-wide association study (PIWAS) and ELISA for epitope validation.

Main Results:

  • 0.44% of somatic mutations were linked to specific antibody responses.
  • PIWAS identified immunogenic motifs in 11 proteins, including NY-ESO-1 and HERVK-113.
  • Validated autoantibody responses to NY-ESO-1 in a separate melanoma cohort.

Conclusions:

  • Presents the first large-scale autoantibody profiling in advanced prostate cancer.
  • Introduces a novel antibody profiling approach revealing new cancer-specific antigens.
  • Identified novel tumor-specific epitopes with potential translational significance for cancer immunotherapy.